• <a fr-original-style="" href="https://www.bloomberg.com/news/articles/2022-01-17/-please-don-t-analysts-scorn-unilever-s-takeover-ambitions?srnd=premium-europe&sref=4TAH79Na" rel="noopener noreferrer" style="color: rgb(9, 9, 9); text-decoration: none; background-color: transparent; outline: none; cursor: pointer; transition: color 0.3s ease 0s; touch-action: manipulation; user-select: auto; box-sizing: border-box;" target="_blank">Unilever's stocks lost almost 7%</a> immediately after reports of the conglomerate's attempted acquisition of GlaxoSmithKline's consumer goods unit in a £50 billion (€60 bn) offer, while gains on GSK stocks bumped up the FTSE to a 2-year high.<ul fr-original-style="padding-inline-start: 20px;" style="padding-inline-start: 20px; margin-top: 0px; margin-bottom: 1em; list-style-position: inside; box-sizing: border-box;"><li fr-original-style="" style="box-sizing: border-box;">What they're saying: Analysts have "almost uniformly" reacted negatively to a potential Unilever buyout, and sources close to GSK's parent Pfizer said that any realistic offer from Unilever would need to be upwards of £60 billion (€72 bn) as the consumer division would be valued at $100 billion (€88 bn) if listed.</li></ul><blockquote fr-original-style="color: rgb(9, 9, 9); border-color: rgb(255, 225, 68); border-width: 4px; font-style: italic; padding-left: 10px;" style="color: rgb(9, 9, 9); border-color: rgb(255, 225, 68); border-width: 4px; font-style: italic; padding-left: 10px; margin: 0px 0px 1em; border-left-style: solid; box-sizing: border-box;">“We can’t imagine many things that would unnerve us more about Unilever than acquiring GSK consumer health.” – James Edwardes Jones of RBC Capital Markets</blockquote>

James Edwardes Jones ile ilgili hikayeler